References
Marnett LJ: Aspirin and the role of prostaglandins in cancer. Cancer Res 52: 5575–5589, 1992
Bennett A. Del Tacca M, Stamford IF, Zebro T: Prostaglandins from tumors of human large bowel. Br J Cancer 35: 881–884, 1977
Narisawa T, Kusaka H, Yamazaki Y,et al.: Relationship between blood plasma prostaglandin E2 and liver and lung metastases in colorectal cancer. Dis Colon Rectum 33: 840–845, 1990
Maxwell WJ, Kelleher D, Keating JJ,et al.: Enhanced secretion of prostaglandin E2 by tissue-fixed macrophages in colonic carcinoma. Digestion 47: 160–166, 1990
Karim SM, Rao B: Prostaglandins and tumors. In: Karim SMM (ed.) Advances in Prostaglandin Research, Vol. 2. MTP Press, Boston, 1976, pp 303–325
Hubbard WC, Alley MC, McLemore TL, Boyd MR: Profiles of prostaglandin biosynthesis in sixteen established cell lines derived from human lung, colon, prostate and ovarian tumors. Cancer Res 48: 4770–4775, 1988
Hubbard WC, Alley MC, McLemore TL, Boyd MR: Fatty acid cyclooxygenase metabolism of arachidonic acid in human tumor cells. In: Honn KV, Marnett LJ, Nigam S, Welden Jr T (eds) Eicosanoids and Other Bioactive Lipids in Cancer and Radiation Injury. Kluwer Academic Publishers, Norwell, M.A., 1991, pp 27–32
Pollard M, Luckert PH: Indomethacin treatment of rats with dimethylhydrazine-induced intestinal tumors. Cancer Treat Rep 64: 1323–1327, 1980
Kudo T, Narisawa T, Abo S: Antitumor activity of indomethacin on methylazoxymethanol-induced large bowel tumors in rats. Gann 71: 260–264, 1980
Pollard M, Luckert PH: Effect of indomethacin on intestinal tumors induced in rats by the acetate derivative of dimethylnitrosamine. Science 214: 558–559, 1981
Pollard M, Luckert PH: Treatment of chemically-induced intestinal cancers with indomethacin. Proc Soc Exp Biol Med 167: 161–164, 1981
Narisawa T, Sato M, Tani M, Kudo T, Takahashi T, Goto A: Inhibition of development of methylnitrosourea-induced rat colon tumors by indomethacin treatment. Cancer Res 41: 1954–1957, 1981
Pollard M, Luckert PH, Schmidt MA: The suppressive effect of piroxicam on autochthonous intestinal tumors in the rat. Cancer Lett 21: 57–61, 1983
Pollard M, Luckert PH: Prolonged antitumor effect of indomethacin on autochthonous intestinal tumors in rats. J Natl Cancer Inst 70: 1103–1105, 1983
Narisawa T, Satoh M, Sano M, Takahashi T: Inhibition of initiation and promotion by N-methylnitrosourea-induced colon carcinogenesis in rats by non-steroid anti-inflammatory agent indomethacin. Carcinogenesis 4: 1225–1227, 1983
Pollard M, Luckert PH: Effect of piroxicam on primary intestinal tumors induced in rats by N-methylnitrosourea. Cancer Lett 25: 117–121, 1984
Narisawa T, Hermanek P, Habs M, Schmahl D: Reduction of carcinogenicity of N-Nitrosomethylurea by indomethacin and failure of resuming effect of Prostaglandin E2 (PGE2) against indomethacin. J Cancer Res Clin Oncol 108: 239–242, 1984
Metzger U, Meier J, Uhlschmid G, Weihe H: Influence of various prostaglandin synthesis inhibitors on DMH-induced rat colon cancer. Dis Colon Rectum 27: 366–369, 1984
Pollard M: Antitumor effect of indomethacin in rats with autochthonous intestinal tumors. In: Levin B, Riddell RH (eds) Frontiers in Gastrointestinal Cancer. Elsevier, New York, 1984, pp 91–103
Nigro DN, Bull AW, Boyd ME: Inhibition of intestinal carcinogenesis in rats: effect of difluoromethylornithine with piroxicam or fish oil. J Natl Cancer Inst 77: 1309–1313, 1986
Reddy BS, Maruyama H, Kelloff G: Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal anti-inflammatory drug, during different stages of rat colon tumor development. Cancer Res 47: 5340–5346, 1987
Moorghen M, Ince P, Finney K, Sunter JP, Appleton DR, Watson AJ: A protective effect of sulindac against chemically-induced primary colonic tumors in mice. J Pathol 156: 341–347, 1988
Pollard M, Luckert PH: Prevention and treatment of primary intestinal tumors in rats by piroxicam. Cancer Res 49: 6471–6473, 1989
Rubio CA, Wallin B, Ware J, Sveander M, Duvander A: Effect of indomethacin in autotransplanted colonic tumors. Dis Colon Rectum 32: 488–491, 1989
Reddy BS, Nayini J, Tokumo K, Rigotty J, Zang E, Kelloff G: Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal anti-inflammatory drug with D,L,-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res 50: 2562–2568, 1990
Rao CV, Tokumo K, Rigotty J, Zang E, Kelloff G, Reddy BS: Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, -difluoromethylornithine, 16-fluoro-5-androsten-17-one, and ellagic acid individually and in combination. Cancer Res 51: 4528–4534, 1991
Skinner SA, Penney AG, O'Brian PE: Sulindac inhibits the rate of growth and appearance of colon tumors in the rat. Arch Surg 126: 1094–1096, 1991
Craven PA, Derubertis FR: Effects of aspirin on 1,-dimethylhydrazine-induced colonic carcinogenesis. Carcinogenesis 13: 541–546, 1992
Reddy BS, Rao CV, Rivenson A, Kelloff G: Inhibitory effects of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 14: 1493–1497, 1993
Weisburger JH, Reddy BS, Joftes DL: Colorectal cancer. UICC Technical Report 19. UICC, Geneva, 1975
Waddell WR, Loughry RW: Sulindac for polyposis of the colon. J Surg Oncol 24: 83–87, 1983
Gonzaga RAF, Lima FR, Carneiro S, Maciel J, Junior MA: Sulindac treatment for familial polyposis coli. Lancet, March 1985, 751 (letter)
Friend WG: Sulindac suppression of colorectal polyps in Gardner's syndrome. AFP 41: 891–894
Waddell WR, Ganser GF, Cerise EJ, Loughry RW: Sulindac for polyposis of the colon. Am J Surg 157: 175–179, 1989
Rigau J, Pigué JM, Rubio E, Planas R, Tarrech JM, Bordas JM: Effects of long-term sulindac therapy on colonic polyposis. Ann Int Med 115: 952–954, 1991
Labayle D, Fischer D, Vielh P,et al.: Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101: 635–639, 1991
Giardiello FM, Hamilton SR, Krush AJ,et al.: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Eng J Med 328: 1313–1316, 1993
Peltomaki P, Aaltonen LA, Sistonen P,et al.: Genetic mapping of a locus predisposing to human colorectal cancer. Science 260: 810–818, 1993
Kune G, Kune S, Watson L: Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 48: 4399–4404, 1988
Paganini-Hill A, Chao A, Ross RK, Henderson BE: Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 229: 1247–1250, 1989
Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S: A Hypothesis: Nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 83: 355–358, 1991
Thun M, Namboodiri M, Heath C: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1593–1596, 1991
Thun M, Namboodiri M, Calle EE, Flanders WD, Heath CW: Aspirin use and risk of fatal cancer. Cancer Res 53: 1322–1327, 1993
Thun MJ, Calle EE, Namboodiri MM,et al.: Risk factors for fatal colon cancer in a large prospective study. J Natl Cancer Inst 84: 1491–1500, 1992
Logan RFA, Little J, Hawtin PG, Hardcastle JD: Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme. BMJ 307: 285–289, 1993
Paganini-Hill AL: Aspirin and colorectal cancer: seems to reduce risk. BMJ 307: 278–279 (editorial), 1993
Peleg II, Maibach HT, Brown SH, Wilcox CM: Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 154: 394–399, 1994
Suh O, Mettlin C, Petrelli NJ: Aspirin use, cancer, and polyps of the large bowel. Cancer 72: 1171–1177, 1993
Isomaki HA, Hakulinen T, Joutsenlahti U: Excess risk of lymphomas, leukemia, and myeloma in patients with rheumatoid arthritis. J Chron Dis 31: 691–696, 1978
Gridley G, McLaughlin JK, Ekbom A,et al.: Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85: 307–311, 1993
Heath CW: heumatoid arthritis, aspirin, and gastrointestinal cancer. J Natl Cancer Inst 85: 258–259 (editorial), 1993
Greenberg ER, Baron JA, Freeman DH, Mandel JS, Haile R: Reduced risk of large-bowel adenomas among aspirin users. J Natl Cancer Inst 85: 912–916, 1993
Schreinemachers DM, Everson RB: Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5: 138–146, 1994
Baron JA, Adami HO: A broad anticancer effect of aspirin? Epidemiology 5: 133–134 (editorial), 1994
Gann PH, Manson JE, Glynn J, Buring J, Hennekins CH: Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 85: 1220–1224, 1993
Lipton A, Scialla S, Harvey H,et al.: Adjuvant antiplatelet therapy with aspirin in colo-rectal cancer. J Med 23: 419–429, 1982
Vane J: Towards a better aspirin. Nature 367: 215–216, 1994
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Thun, M.J. Aspirin, NSAIDs, and digestive tract cancers. Cancer Metast Rev 13, 269–277 (1994). https://doi.org/10.1007/BF00666097
Issue Date:
DOI: https://doi.org/10.1007/BF00666097